Y Intercept (Hong Kong) LTD Novo Cure LTD Transaction History

Y Intercept (Hong Kong) LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$12.42 - $17.29 $699,270 - $973,461	56,302 Added 83.24%	123,939 $1.94 Million
Q4 2023 Feb 13, 2024	BUY	$11.13 - $15.78 $192,037 - $272,268	17,254 Added 34.25%	67,637 $1.01 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $813,685 - $2.13 Million	50,383 New	50,383 $813,000
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $315,667 - $443,560	-5,248 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $58,187 - $94,542	-775 Reduced 12.87%	5,248 $394,000
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $699,691 - $1.17 Million	6,023 New	6,023 $700,000
Q2 2021 Aug 12, 2021	SELL	$130.4 - $225.58 $813,565 - $1.41 Million	-6,239 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$124.11 - $190.17 $774,322 - $1.19 Million	6,239 New	6,239 $781,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.77B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.